Publications by authors named "Mary Doi"

Claim this Profile
P
Pivotal trial characteristics and types of endpoints used to support Food and Drug Administration rare disease drug approvals between 2013 and 2022.
Kyungwan Hong, Bridget Nugent, Abbas Bandukwala, Robert Schuck, York Tomita, Mary Doi

Clin Trials· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Confirmatory Evidence Used in Non-Oncologic Rare Disease New Molecular Entity Marketing Applications Approved by FDA, 2020-2023.
Bridget M Nugent, Anuradha Ramamoorthy, Jennifer R Pippins, Salvatore Pepe, Mary Doi

Clin Pharmacol Ther· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dose-finding studies in drug development for rare genetic diseases.
Lingshan Wang, Jie Wang, Ji Feng, Mary Doi, Salvatore Pepe

Orphanet J Rare Dis· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Informal and formal support among community-dwelling Japanese American elders living alone in Chicagoland: an in-depth qualitative study.
Denys T Lau, Sayaka Machizawa, Mary Doi

J Cross Cult Gerontol· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A comparison of rapid and conventional measures of indicator bacteria as predictors of waterborne protozoan pathogen presence and density.
Samuel Dorevitch, Mary Doi, Fu-Chih Hsu, King-Teh Lin, Jennifer D Roberts

J Environ Monit· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis